Endogenous neuropeptide
Nociceptin
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Nociceptin →Peptide directory
Find a peptide
Public profiles inside a larger governed registry
Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.
The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.
Published profiles
Search profiles and sources
Endogenous neuropeptide
Nocistatin
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Nocistatin →Endogenous peptide
Obestatin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Obestatin →Somatostatin analog
Octreotate
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Octreotate →- Developing
Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Growth-factor-related cosmetic nomenclature/reference
Oligopeptide-1
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Oligopeptide-1 →Synthetic antimicrobial peptide
Omiganan
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Omiganan →Endogenous neuropeptide
Orexin A
Published sources available; full evidence profile in development.
3 published source records. Source publication does not imply scientific appraisal.
Open sources for Orexin A →Endogenous neuropeptide
Orexin B
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Orexin B →Lipoglycopeptide antibiotic
Oritavancin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Oritavancin →Research reference
Ornipressin
Published sources available; full evidence profile in development.
1 published source records. Source publication does not imply scientific appraisal.
Open sources for Ornipressin →Endogenous peptide/protein hormone
Osteocalcin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Osteocalcin →PTHrP-derived peptide fragment
Osteostatin
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Osteostatin →Peptide mixture/reference entity
Ovagen
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for Ovagen →Oxidized endogenous peptide
Oxidized glutathione
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Oxidized glutathione →- Developing
Oxytocin is an endogenous nonapeptide hormone and neurotransmitter synthesized primarily in hypothalamic neurons and released from the posterior pituitary; it also acts locally in reproductive tissues and the central nervous system. By activating the oxytocin receptor, a G-protein-coupled receptor, it promotes uterine smooth-muscle contraction and myoepithelial contraction for milk ejection. Synthetic oxytocin is an established obstetric medicine, while many behavioral and neuropsychiatric applications remain investigational and context-dependent.
Evidence and record details
Evidence integrity map
Human 1Preclinical 0Durable IDs 7Open signals 1- Publication state
- Published profile
- Verified source records
- 25 source records verified
- Chemistry record
- Chemistry record on file
- Regulatory entries
- 2 published regulatory entries
- Research questions
- No open questions documented
- Evidence review date
- No documented human review recorded
Source verification checks records; it does not itself approve scientific conclusions.
Research peptide
P21 peptide
Published sources available; full evidence profile in development.
2 published source records. Source publication does not imply scientific appraisal.
Open sources for P21 peptide →Lipopeptide cosmetic ingredient
Palmitoyl pentapeptide-4
Published sources available; full evidence profile in development.
4 published source records. Source publication does not imply scientific appraisal.
Open sources for Palmitoyl pentapeptide-4 →
How the public directory relates to the 500-record Master Registry
master registry transparency
500 master records, with governance status shown explicitly
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators
The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.
Explore the full Master Registry →What the profile status labels mean
Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.
Recently updated public records
When each public profile record was last changed — not clinical or scientific activity.